Literature DB >> 20331945

Assessing emerging infectious threats to blood safety for the blood disorders community.

Sean R Trimble1, Christopher S Parker, Althea M Grant, J Michael Soucie, Nimia Reyes.   

Abstract

Technologic advances in diagnostic testing, vaccinations, pathogen inactivation, and vigilant donor screening have greatly reduced the risk of transmitting pathogens through blood transfusion. Nevertheless, transfusion-related infections and fatalities continue to be reported, and emerging pathogens continue to become an increasing threat to the blood supply. This threat is even greater to patients with blood disorders, who are heavily transfused and rely on safe blood products. This article describes some of the emerging and re-emerging transfusion-transmitted pathogens that have increased in incidence in the U.S. in recent years. Peer-reviewed articles and agency websites were the sources of information. The article focuses on the treatment of hereditary blood disorders including hemophilia and thalassemia, and hereditary bone marrow failure. A coordinated approach to addressing blood safety and continued development of sensitive diagnostic testing are necessary to reduce risk in an increasingly globalized society. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20331945     DOI: 10.1016/j.amepre.2009.12.019

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  4 in total

1.  Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Authors:  Giovanni Di Minno; Mariana Canaro; James W Ironside; David Navarro; Carlo Federico Perno; Andreas Tiede; Lutz Gürtler
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  [Acknowledged risks in transfusion and impact of taken measures on those risks].

Authors:  Olivier Garraud
Journal:  Transfus Clin Biol       Date:  2011-06-12       Impact factor: 1.406

Review 3.  Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Authors:  Giovanni Di Minno; Carlo Federico Perno; Andreas Tiede; David Navarro; Mariana Canaro; Lutz Güertler; James W Ironside
Journal:  Blood Rev       Date:  2015-07-20       Impact factor: 8.250

Review 4.  Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study.

Authors:  A A Hanke; C Joch; K Görlinger
Journal:  Br J Anaesth       Date:  2013-01-18       Impact factor: 9.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.